Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer

Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer

ER+ breast cancers (BC) are characterized by the elevated expression and signaling of estrogen receptor alpha (ESR1), which renders them sensitive to anti-endocrine therapy. While these therapies are clinically effective, prolonged treatment inevitably results in therapeutic resistance, which can oc...

Full description

Saved in:
Bibliographic Details
Main Authors: Gabrielle P. Dailey, Christopher A. Rabiola, Gangjun Lei, Junping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Melissa Gajda, Amy C. Hobeika, Amanda Summers, Robert D. Marek, Michael A. Morse, Herbert K. Lyerly, Erika J. Crosby, Zachary C. Hartman
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Breast cancer
estrogen receptor
neoepitopes
resistance mutations
cancer vaccines
preventative vaccination
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2024.2309693
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items